Atlas Trials

CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia

Clinical trial NCT04265963 · UNKNOWN

Trial details

NCT number
NCT04265963
Sponsor
Chongqing Precision Biotech Co., Ltd
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
LeukemiaLeukemia, MyeloidLeukemia, Myeloid, Acute
Start date
2019-09-01
Primary completion
2023-12-31
Enrollment
45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.